About Supha Pharmachem Limited
Data last updated: 06 January 2026
Supha Pharmachem Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 19 February 1988, the company has been in operation for over 38 years.
Registered with ROC Mumbai under CIN L24100MH1988PLC343805. Listed on BSE: 539561.
Capital: an authorised share capital of ₹110 Cr and a paid-up capital of ₹88.2 Cr. Formerly known as Roxy Exports Limited and Supha Pharmachem Limited. It is led by directors including Vijay Pal Singh Gulya and Mansoor Vahab.
Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹233.3 Cr, a decline of 94% compared to the previous year.
The company has a workforce of approximately 6 employees as per the latest available data.
The company is associated with 2 brands - Remedium Lifecare, Roxy Exports. As per MCA filings, the company has satisfied charges of ₹3.26 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website remediumlifecare.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressOffice No.9 K Raheja Prime Marol Industrial Estate, Behind Ravi Vihar Hotel Sagbaug Road Marol Andheri East, Mumbai, Maharashtra, India – 400059
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Supha Pharmachem Limited
Supha Pharmachem Limited has undergone 2 name changes throughout its history. The company was previously known as Roxy Exports Limited, and Supha Pharmachem Limited. The current legal name is Supha Pharmachem Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Supha Pharmachem Limited | Current |
| Roxy Exports Limited | Previous |
CIN History of Supha Pharmachem Limited
Supha Pharmachem Limited has 4 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100MH1988PLC343805, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100MH1988PLC343805 | Current |
| L51909PB1988PLC008009 | Previous |
| L29100MH1988PLC343805 | Previous |
| U51909PB1988PLC008009 | Previous |
| L29100PB1988PLC008009 | Previous |
Associated Brands with Supha Pharmachem Limited
Supha Pharmachem Limited operates two associated brands: Remedium Lifecare and Roxy Exports. These brands represent Supha Pharmachem Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Trading of pharmaceutical APIs and intermediates is conducted in domestic and international markets. | remediumlifecare.com | |
| Solutions for generating water from atmospheric air are provided. | roxyexports.in |
Competitors & Alternatives of Supha Pharmachem Limited
Brands and companies operating in the same space as Supha Pharmachem Limited include Uravu Labs, Kara Water, SunToWater Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Uravu Labs
|
Developer of air-to-water generating systems | Bengaluru, India, India | 2019 |
Kara Water
|
Manufacturer of air-to-water devices producing mineral-rich alkaline water and coffee | New York, United States, United States | 2017 |
SunToWater Technologies
|
Water is generated from air via solar-powered dehumidification systems. | Palo Alto, United States, United States | 2012 |
Akvo
|
Water is generated from air using innovative atmospheric technology. | Kolkata, India, India | 2016 |
Majik Water
|
Water is harvested from air using solar-powered intake fans. | Nairobi, Kenya, Kenya | 2017 |
Drinkable Air Technologies
|
Provider of products that produce water from air | Fort Lauderdale, United States, United States | 2010 |
Atmospheric Water Solutions
|
Atmospheric water generators are supplied for residential and commercial applications. | Cooper City, United States, United States | 2011 |
ThinAir Water
|
Delivers innovative solutions using water-from-air technology. | London, United Kingdom, United Kingdom | 2016 |
AquaPoro
|
Creates atmospheric water generators for residential, commercial, and municipal use. | Amman, Jordan, Jordan | 2022 |
Business Activity of Supha Pharmachem Limited
Supha Pharmachem Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Supha Pharmachem Limited
Supha Pharmachem Limited is audited by TAORI SANDEEP & ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| TAORI SANDEEP & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Supha Pharmachem Limited
Supha Pharmachem Limited is currently managed by 11 directors, with 30 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Vijay Pal Singh Gulya
Also directs:
Supha Pharmachem Limited, Eduworth Clothings And Accessories Private Limited, Blaze Electronics Pvt.Ltd. and 1 more
|
Director | 30 May 2025 | 1 Years 1 Months | Current |
|
Mansoor Vahab
Also directs:
Supha Pharmachem Limited
|
Director | 31 Oct 2024 | 1 Years 8 Months | Current |
|
Bikram Kumar Mund
Also directs:
Supha Pharmachem Limited, True Value Propmart Private Limited, Carvan Builders Private Limited and 2 more
|
Director | 30 May 2025 | 1 Years 1 Months | Current |
|
Seema Sanei
Also directs:
Supha Pharmachem Limited
|
Additional Director | 11 Apr 2024 | 2 Years 2 Months | Current |
|
Hanosh Sam Santok
Also directs:
Supha Pharmachem Limited
|
Director | 30 Sep 2019 | 6 Years 9 Months | Current |
|
Adarsh Deepak Munjal
Also directs:
Supha Pharmachem Limited, Risevertise Media Llp
|
Director | 05 Sep 2023 | 2 Years 10 Months | Current |
Financials of Supha Pharmachem Limited FY 2025 filings available
Supha Pharmachem Limited reported revenue of ₹405.25 Cr (up ) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2025 |
|---|---|
| Revenue from Operations | ₹405.25 Cr |
| Other Income | ₹10.8 Cr |
| Total Income | ₹416.05 Cr |
| Cost of Materials Consumed | ₹0 |
| Purchases of Stock-in-Trade | ₹534.28 Cr |
| Changes in Inventories | -₹136.15 Cr |
| Employee Benefit Expense | ₹75.6 Lakh |
| Finance Costs | ₹5.29 Cr |
| Depreciation & Amortisation | ₹3.87 Lakh |
| Other Expenses | ₹7.45 Cr |
| Total Expenses | ₹411.67 Cr |
| Profit Before Exceptional Items & Tax | ₹4.38 Cr |
| Exceptional Items | ₹0 |
| Profit Before Tax | ₹4.38 Cr |
| Total Tax Expense | ₹2.25 Cr |
| Net Profit | ₹2.13 Cr |
| attributable to Owners | ₹59.74 Lakh |
| attributable to NCI | ₹0 |
| Other Comprehensive Income | ₹0 |
| Total Comprehensive Income | ₹2.13 Cr |
| EBITDA (computed) | ₹9.71 Cr |
| Basic EPS | ₹0.05 |
| Diluted EPS | ₹0.05 |
| Metrics | FY 2025 |
|---|---|
| Total Assets | ₹1,720.35 Cr |
| Non-current Assets | ₹4.41 Lakh |
| Current Assets | ₹1,720.31 Cr |
| Property, Plant & Equipment | ₹83,000 |
| Inventories | ₹269.38 Cr |
| Trade Receivables | ₹771.62 Cr |
| Cash & Equivalents | ₹28.15 Lakh |
| Equity (Net Worth) | ₹43.89 Cr |
| Equity Share Capital | ₹40.32 Cr |
| Borrowings (Non-current) | ₹0 |
| Borrowings (Current) | ₹1,141.39 Cr |
| Total Debt (computed) | ₹1,141.39 Cr |
| Current Liabilities | ₹1,676.46 Cr |
| Total Liabilities | ₹1,676.46 Cr |
| Metrics | FY 2025 |
|---|---|
| Operating Cash Flow | -₹1,134.81 Cr |
| Investing Cash Flow | ₹12.89 Lakh |
| Financing Cash Flow | ₹1,136.1 Cr |
| Capital Expenditure | ₹0 |
| Free Cash Flow (computed) | -₹1,134.81 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | ₹1.43 Cr |
| Metrics | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from Operations | ₹111.06 Cr | ₹113.37 Cr | ₹264.32 Cr |
| Other Income | ₹3.25 Cr | ₹3.48 Cr | ₹65.93 Lakh |
| Total Income | ₹114.31 Cr | ₹116.84 Cr | ₹264.98 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹98.03 Cr | ₹101.69 Cr | ₹191.01 Cr |
| Changes in Inventories | ₹2.45 Cr | ₹6.14 Cr | ₹71.66 Cr |
| Employee Benefit Expense | ₹19.07 Lakh | ₹19.6 Lakh | ₹9.27 Lakh |
| Finance Costs | ₹18.72 Lakh | -₹36.49 Lakh | ₹1.59 Cr |
| Depreciation & Amortisation | ₹3,000 | ₹1,000 | ₹97,000 |
| Other Expenses | ₹3.02 Cr | ₹3.47 Cr | ₹2.02 Cr |
| Total Expenses | ₹103.88 Cr | ₹111.13 Cr | ₹266.38 Cr |
| Profit Before Exceptional Items & Tax | ₹10.44 Cr | ₹5.71 Cr | -₹1.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹10.44 Cr | ₹5.71 Cr | -₹1.4 Cr |
| Total Tax Expense | ₹1.81 Cr | ₹1.06 Cr | ₹64.56 Lakh |
| Net Profit | ₹8.62 Cr | ₹4.65 Cr | -₹2.05 Cr |
| attributable to Owners | ₹0 | ₹5.01 Cr | ₹59.74 Lakh |
| attributable to NCI | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹8.62 Cr | ₹4.65 Cr | -₹2.05 Cr |
| EBITDA (computed) | ₹10.62 Cr | ₹5.35 Cr | ₹20.26 Lakh |
| Basic EPS | ₹0.10 | ₹0.05 | ₹-0.05 |
| Diluted EPS | ₹0.10 | ₹0.05 | ₹-0.05 |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹222.5 Cr | ₹4,041.71 Cr | ₹509.84 Cr | ₹504.79 Cr | ₹90.03 Cr | ₹2.89 Cr | ₹15.91 Lakh |
| Other Income | ₹10.8 Cr | ₹21.08 Cr | ₹400 | ₹400 | ₹20,500 | ₹0 | ₹8.8 Lakh |
| Total Income | ₹233.3 Cr | ₹4,062.79 Cr | ₹509.84 Cr | ₹504.79 Cr | ₹90.04 Cr | ₹2.89 Cr | ₹24.71 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹498.47 Cr | ₹87.74 Cr | ₹1.67 Cr | ₹4.51 Lakh |
| Purchases of Stock-in-Trade | ₹352.26 Cr | ₹4,127.28 Cr | ₹417.3 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹136.15 Cr | -₹125.91 Cr | ₹76.55 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹75.6 Lakh | ₹84.27 Lakh | ₹98.33 Lakh | ₹53.32 Lakh | ₹18.8 Lakh | ₹18.38 Lakh | ₹4.06 Lakh |
| Finance Costs | ₹5.29 Cr | ₹3.87 Cr | -₹7.55 Lakh | ₹10.7 Lakh | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹3.87 Lakh | ₹5.67 Lakh | ₹15.08 Lakh | ₹7.38 Lakh | ₹6.01 Lakh | ₹1.32 Lakh | ₹0 |
| Other Expenses | ₹7.44 Cr | ₹6.19 Cr | ₹7.53 Cr | ₹4.08 Cr | ₹1.4 Cr | ₹64.42 Lakh | ₹14.22 Lakh |
| Total Expenses | ₹229.64 Cr | ₹4,012.33 Cr | ₹502.44 Cr | ₹503.27 Cr | ₹89.38 Cr | ₹2.52 Cr | ₹22.79 Lakh |
| Profit Before Exceptional Items & Tax | ₹3.66 Cr | ₹50.45 Cr | ₹7.4 Cr | ₹1.53 Cr | ₹65.29 Lakh | ₹37.5 Lakh | ₹1.92 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹3.66 Cr | ₹50.45 Cr | ₹7.4 Cr | ₹1.53 Cr | ₹65.29 Lakh | ₹37.5 Lakh | ₹1.92 Lakh |
| Total Tax Expense | ₹2.13 Cr | ₹17.72 Cr | ₹1.97 Cr | ₹44.73 Lakh | ₹17.24 Lakh | ₹9.8 Lakh | ₹1.12 Lakh |
| Net Profit | ₹1.53 Cr | ₹32.73 Cr | ₹5.43 Cr | ₹1.08 Cr | ₹48.05 Lakh | ₹27.7 Lakh | ₹80,000 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.53 Cr | ₹32.73 Cr | ₹5.43 Cr | ₹1.08 Cr | ₹48.05 Lakh | ₹27.7 Lakh | ₹80,000 |
| EBITDA (computed) | ₹8.99 Cr | ₹54.38 Cr | ₹7.47 Cr | ₹1.71 Cr | ₹71.29 Lakh | ₹38.81 Lakh | ₹1.92 Lakh |
| Basic EPS | ₹0.04 | ₹3.25 | ₹15.07 | ₹2.99 | ₹0.72 | ₹0.77 | ₹0.02 |
| Diluted EPS | ₹0.04 | ₹3.25 | ₹15.07 | ₹2.99 | ₹0.72 | ₹0.77 | ₹0.02 |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹1,539.65 Cr | ₹1,947.92 Cr | ₹1,154.22 Cr | ₹223.76 Cr | ₹38.53 Cr | ₹4.27 Cr | ₹3.53 Cr |
| Non-current Assets | ₹10.92 Lakh | ₹7.37 Lakh | ₹8.55 Lakh | ₹18.61 Lakh | ₹21.01 Lakh | ₹23.12 Lakh | ₹4,000 |
| Current Assets | ₹1,539.54 Cr | ₹1,947.85 Cr | ₹1,154.14 Cr | ₹223.57 Cr | ₹38.32 Cr | ₹4.04 Cr | ₹3.53 Cr |
| Property, Plant & Equipment | ₹83,000 | ₹4.7 Lakh | ₹7.81 Lakh | ₹8.54 Lakh | ₹7.3 Lakh | ₹5.79 Lakh | ₹0 |
| Inventories | ₹269.38 Cr | ₹133.23 Cr | ₹7.32 Cr | ₹83.87 Cr | ₹3.11 Cr | ₹70.12 Lakh | ₹20.47 Lakh |
| Trade Receivables | ₹590.92 Cr | ₹920.6 Cr | ₹172.37 Cr | ₹64 Cr | ₹23.68 Cr | ₹1.5 Cr | ₹13.7 Lakh |
| Cash & Equivalents | ₹28.15 Lakh | ₹27.07 Lakh | ₹24.36 Lakh | ₹69.8 Lakh | ₹66.31 Lakh | ₹84.05 Lakh | ₹1.07 Cr |
| Equity (Net Worth) | ₹43.3 Cr | ₹42.96 Cr | ₹10.36 Cr | ₹4.94 Cr | ₹3.86 Cr | ₹3.35 Cr | ₹3.08 Cr |
| Equity Share Capital | ₹40.32 Cr | ₹10.08 Cr | ₹3.6 Cr | ₹3.6 Cr | ₹3.6 Cr | ₹3.6 Cr | ₹3.6 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 | ₹10.5 Cr | ₹36.43 Lakh | ₹0 |
| Borrowings (Current) | ₹1,141.39 Cr | ₹57.7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.6 Lakh |
| Total Debt (computed) | ₹1,141.39 Cr | ₹57.7 Cr | ₹0 | ₹0 | ₹10.5 Cr | ₹36.43 Lakh | ₹7.6 Lakh |
| Current Liabilities | ₹1,496.35 Cr | ₹1,904.97 Cr | ₹1,143.86 Cr | ₹218.82 Cr | ₹24.17 Cr | ₹54.67 Lakh | ₹44.95 Lakh |
| Total Liabilities | ₹1,496.35 Cr | ₹1,904.97 Cr | ₹1,143.86 Cr | ₹218.82 Cr | ₹34.68 Cr | ₹91.47 Lakh | ₹44.95 Lakh |
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹1,078.63 Cr | -₹74.16 Cr | ₹20.5 Cr | ₹11.28 Cr |
| Investing Cash Flow | ₹6.38 Lakh | ₹0 | -₹4.27 Lakh | -₹4.98 Lakh |
| Financing Cash Flow | ₹1,078.4 Cr | ₹53.83 Cr | -₹3.74 Lakh | -₹10.61 Cr |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹4.98 Lakh |
| Free Cash Flow (computed) | -₹1,078.63 Cr | -₹74.16 Cr | ₹20.5 Cr | ₹11.23 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹16.01 Lakh | -₹20.33 Cr | ₹20.42 Cr | ₹62.49 Lakh |
| Metrics | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹8.58 Cr | ₹18.37 Cr | ₹81.57 Cr | ₹38.15 Cr | ₹25.08 Cr | ₹77.7 Cr |
| Other Income | ₹3.25 Cr | ₹3.48 Cr | ₹65.93 Lakh | ₹7.43 Cr | ₹82.23 Lakh | ₹1.89 Cr |
| Total Income | ₹11.83 Cr | ₹21.85 Cr | ₹82.23 Cr | ₹45.58 Cr | ₹25.9 Cr | ₹79.59 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹5.91 Cr | ₹12.81 Cr | ₹8.98 Cr | ₹77.7 Cr | ₹115.39 Cr | ₹150.18 Cr |
| Changes in Inventories | ₹2.45 Cr | ₹6.14 Cr | ₹71.66 Cr | -₹37.27 Cr | -₹96.44 Cr | -₹74.1 Cr |
| Employee Benefit Expense | ₹19.07 Lakh | ₹19.6 Lakh | ₹9.27 Lakh | ₹20.29 Lakh | ₹23.8 Lakh | ₹22.24 Lakh |
| Finance Costs | ₹18.72 Lakh | -₹36.49 Lakh | ₹1.59 Cr | ₹88.36 Lakh | ₹2.81 Cr | ₹0 |
| Depreciation & Amortisation | ₹3,000 | ₹1,000 | ₹97,000 | ₹96,700 | ₹96,700 | ₹96,700 |
| Other Expenses | ₹3.02 Cr | ₹3.43 Cr | ₹2.01 Cr | ₹2.99 Cr | ₹1.43 Cr | ₹1.01 Cr |
| Total Expenses | ₹11.76 Cr | ₹22.22 Cr | ₹84.35 Cr | ₹44.52 Cr | ₹23.44 Cr | ₹77.32 Cr |
| Profit Before Exceptional Items & Tax | ₹7.38 Lakh | -₹36.51 Lakh | -₹2.12 Cr | ₹1.06 Cr | ₹2.46 Cr | ₹2.27 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹7.38 Lakh | -₹36.51 Lakh | -₹2.12 Cr | ₹1.06 Cr | ₹2.46 Cr | ₹2.27 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹52.32 Lakh | ₹29.47 Lakh | ₹68.41 Lakh | ₹63.05 Lakh |
| Net Profit | ₹7.38 Lakh | -₹36.51 Lakh | -₹2.64 Cr | ₹76.45 Lakh | ₹1.77 Cr | ₹1.64 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹7.38 Lakh | -₹36.51 Lakh | -₹2.64 Cr | ₹76.45 Lakh | ₹1.77 Cr | ₹1.64 Cr |
| EBITDA (computed) | ₹26.13 Lakh | -₹72.99 Lakh | -₹51.72 Lakh | ₹1.95 Cr | ₹5.28 Cr | ₹2.28 Cr |
| Basic EPS | ₹0.00 | ₹0.00 | ₹-0.07 | ₹0.02 | ₹0.04 | ₹0.16 |
| Diluted EPS | ₹0.00 | ₹0.00 | ₹-0.07 | ₹0.02 | ₹0.04 | ₹0.16 |
Shareholding Pattern of Supha Pharmachem Limited
As per the shareholding pattern filed with BSE for the quarter ended Dec 2025, promoters hold 1.13%, foreign institutional investors hold 1.70%, retail and other public shareholders hold 97.17% of Supha Pharmachem Limited. The company had 111,269 shareholders on record.
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 1.13% | 1.13% | 1.13% | 1.11% | 1.11% | 1.11% |
| Public | 98.87% | 98.87% | 98.87% | 98.89% | 98.89% | 98.89% |
| Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|
| Promoters | 1.11% | 1.11% | 1.11% |
| Public | 98.89% | 98.89% | 98.89% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Charges & Borrowings of Supha Pharmachem Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Mar 2012 | Indian Overseas Bank | ₹95 Lakh | Satisfied |
| 07 Jan 2011 | Indian Overseas Bank | ₹1.5 Cr | Satisfied |
| 20 Feb 1996 | Punjab National Bank | ₹6 Lakh | Satisfied |
| 02 Aug 1995 | Punjab National Bank | ₹2.5 Lakh | Satisfied |
| 24 Apr 1995 | Punjab National Bank | ₹15 Lakh | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Supha Pharmachem Limited
Supha Pharmachem Limited has a workforce of 6 employees as of Mar 29, 2024.
Employee Count & EPFO Data of Supha Pharmachem Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Supha Pharmachem Limited
GSTIN & GST Filing Data of Supha Pharmachem Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Supha Pharmachem Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Supha Pharmachem Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Supha Pharmachem Limited
MSME Payment Delays by Supha Pharmachem Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Supha Pharmachem Limited
Subsidiaries & Group Companies of Supha Pharmachem Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Supha Pharmachem Limited with ownership details.
MCA Filings & Documents of Supha Pharmachem Limited
MCA Filings & Documents of Supha Pharmachem Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Supha Pharmachem Limited
Recent News on Supha Pharmachem Limited
Frequently Asked Questions about Supha Pharmachem Limited
Supha Pharmachem Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 19 February 1988 (38+ years old) and is registered under CIN L24100MH1988PLC343805. Listed on BSE: 539561. The company has 6 employees.
Supha Pharmachem Limited reported revenue of ₹233.3 Cr for FY 2025 (down 94.00% YoY).
The current directors of Supha Pharmachem Limited are:
The primary industry of Supha Pharmachem Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Yes. Supha Pharmachem Limited is listed on BSE with code 539561.
Supha Pharmachem Limited can be reached at the registered office: Office No.9 K Raheja Prime Marol Industrial Estate, Behind Ravi Vihar Hotel Sagbaug Road Marol Andheri East, Mumbai, Maharashtra, India – 400059, or through the website remediumlifecare.com.